A phase III trial of remetinostat for the treatment of cutaneous T-cell lymphoma
Phase of Trial: Phase III
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Remetinostat (Primary)
- Indications Cutaneous T cell lymphoma
- Focus Therapeutic Use
- 07 Apr 2017 According to a Medivir AB media release, based on the data from Phase II trial (see profile 243325) company is planning to initiate discussions with regulatory authorities with the aim of initiating this trial later in 2017.
- 14 Nov 2016 New trial record
- 02 Nov 2016 According to a Medivir AB media release, the company plans to initiate this trial in the second half of 2017.